All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How is CT053 different from other BCMA-directed CAR T-cell therapies?

Dec 17, 2020

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Shaji K. Kumar, Mayo Clinic, Rochester, US. We asked, How is CT053 different from other B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies?

CT053 consists of autologous T cells genetically modified with a CAR incorporating a fully human BCMA-specific single-chain fragment variant, a 4-1BB intracellular domain, and a CD3 intracellular signaling region. The advantage over other CAR T-cell therapies is that it has a shorter manufacturing time, of 8–10 days, which allows a shorter interval between apheresis and infusion. Kumar reports the results of an ongoing phase I/II trial evaluating the safety and efficacy of CT053 in patients with relapsed/refractory multiple myeloma.